Lord Walton of Detchant

To ask Her Majesty’s Government whether appropriate treatment for patients with plasma disorders such as haemophilia and primary immunodeficiency, as provided for under the statutory scheme for branded medicines, will continue to be provided following the...

To ask Her Majesty’s Government why the acute adult dermatology service at Nottingham University Hospital is to be closed; and whether they have assessed the effect that that decision will have upon patients in the area affected by skin diseases.

To ask Her Majesty’s Government what effect they consider the loss of six consultant dermatologists in Nottingham will have upon direct services to the local community and the training of junior doctors and medical students.

To ask Her Majesty’s Government how they propose to respond to the survey of Acute Neurology Services issued by the Association of British Neurologists in December; and what action they plan to take to ensure that clearly defined quality standards in acut...

To ask Her Majesty’s Government why they have withdrawn approval of the drug Translarna, introduced for the treatment of Duchenne muscular dystrophy, despite the preliminary results achieved in some patients in trials in Newcastle upon Tyne.

To ask Her Majesty’s Government whether they will publish a report on the work of the Rare Diseases Advisory Group, indicating the extent to which its recommendations have influenced the decisions of the National Institute for Health and Care Excellence a...

To ask Her Majesty’s Government when they intend to bring forward regulations which will permit the implantation of embryos free of harmful mitochondrial mutations into the uterus of women carrying such harmful mutations.

To ask Her Majesty’s Government how they propose to make available for prescription under the National Health Service orphan and ultra-orphan drugs for the treatment of rare diseases now emerging as a result of recent research discoveries.

To ask Her Majesty’s Government whether, in view of developments in genomic medicine and the case for communicating accurately and sensitively the significance of genomic data to patients, they will reconsider the possibility of mandatory registration of ...

To ask Her Majesty's Government how individual funding requests relating to the prescription of Duodopa for patients with advanced Parkinsonism are handled in the National Health Service.

To ask Her Majesty's Government what advice the Clinical Priorities Advisory Group received about the routine use of Duodopa for advanced Parkinson's disease.

To ask Her Majesty's Government what estimate they have made of the uptake of innovative anti-coagulant medicines in the management of venous thromboembolism in the National Health Service.

To ask Her Majesty's Government what steps they are taking to ensure access to innovative medicines in order to improve the management of venous thromboembolism in the National Health Service.

To ask Her Majesty's Government what effect the new proposals for value-based assessments published by the National Institute for Healthand Care Excellence on 22 March 2014 have had on the availability of treatments to patients with (1) those forms of can...

To ask Her Majesty's Government what assessment they have made of the impact of the proposals for value-based assessments published by the National Institute for Healthand Care Excellence on 22 March 2014 on patients' access to new cancer medicines.